Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis

It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment.

‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL.‘ was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.

Questions

1. What did the Phase 3 ASTERA study teach us about the efficacy and safety of netakimab in patients with ankylosing spondylitis? (0:17)
2. What are the clinical consequences of sacroiliitis in patients with ankylosing spondylitis? (1:31)
3. Could you tell us a little about your recent sub analysis of the ASTERA trial data? (2:21)
4. What are the wider implications of these findings? (4:02)

Disclosures: Inna Gaydukova has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of EULAR 2021 (Virtual).